NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
TRIOSTAT (liothyronine sodium) by Pfizer is synthesis. Approved for multiple sclerosis. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIOSTAT (liothyronine sodium) is an injectable thyroid hormone replacement therapy that acts as a synthetic triiodothyronine (T3), binding to nuclear thyroid receptors to modulate gene transcription and metabolic processes. It is indicated for multiple sclerosis, where thyroid hormone signaling may modulate immune function and neuroinflammation. The drug's mechanism relies on T3-mediated activation of cellular protein synthesis and metabolic rate regulation.
LOE Approaching
As a legacy injectable with LOE approaching, this product likely operates with a lean, specialized team focused on retention rather than growth, offering limited expansion opportunities.
Mechanism of Action
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Worked on TRIOSTAT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.